New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 5, 2014
06:41 EDTCTICCTI BioPharma upgraded to Buy from Hold at WallachBeth
WallachBeth upgraded CTI BioPharma to Buy with a $4.50 price target citing the recent pullback in shares. The firm believes the company's Pacritinib is a differentiated JAK2 kinase inhibitor from Jakafi with less thrombocytopenia.
News For CTIC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 17, 2015
12:38 EDTCTICCTI BioPharma management to meet with Piper Jaffray
Subscribe for More Information
March 16, 2015
09:15 EDTCTICCTI BioPharma shares should be bought on weakness, says Roth Capital
Subscribe for More Information
05:27 EDTCTICCTI BioPharma announces publication of Phase 2 pacritinib study results
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use